

24 Abstract

25 Due to the currently increasing case numbers of SARS-CoV-2 infections worldwide there is
26 an increasing need for rapid diagnostic devices in addition to existing PCR-capacities.
27 Therefore, rapid antigen assays including lateral flow assays are discussed as an alternative
28 method. In comparison to an established RT-PCR protocol, however the novel lateral flow
29 assay unfortunately lowered the expectations set in these assays.

31 Brief Communication

32 In December 2019 the public became aware of the new betacoronavirus SARS-CoV-2 due to
33 an outbreak in Wuhan, China (1). Very soon it turned out that spreading of the virus cannot
34 be prevented and Covid-19 was declared a pandemic in March 2020
35 (<https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic>). In order to minimize the
36 risk of infection different undirected as well as targeted tracking strategies were developed,
37 whose success is dependent on extensive testing of the largest possible number of people
38 (2). For SARS-CoV-2 detection different PCRs are used in routine diagnostic. Although these
39 PCRs are actually the “gold” standard (3), valuable time passes until the result is available
40 (<https://www.nytimes.com/2020/08/04/us/virus-testing-delays.html>). Since it was shown that
41 rapid antibody screenings are not suitable to evaluate chains of infection or their interruption,
42 other kinds of rapid on-site tests are needed to perform the requested mass testing.

44 One of these is the BIOCREDIT COVID-19 Ag test of RapiGENJNC (Korea). This lateral flow
45 test is based on immunochromatography and shows SARS-CoV-2 antigen presence by
46 staining with colloid gold conjugate as a black test line. According to the manufacturer’s
47 instruction it should support early diagnosis of Covid-19 infections in patients with clinical
48 symptoms. Sampling should be performed in the nasopharynx with the supplied swab, but
49 UTM/VTM media is also appropriate if diluted 1:2 with assay buffer. Moreover it has been
50 shown that specimen other than nasopharyngeal swaps have comparable diagnostic
51 sensitivity (4)(5). For this reason we tested a pilot sample panel of 11 BALFs
52 (bronchoalveolar lavage fluid) and 70 throat washing samples with confirmed PCR results
53 (RealStar® SARS-CoV-2 RT-PCR Kit, Altona, Germany), as well as 9 throat washes invalid
54 by PCR. First, we evaluated if the BIOCREDIT assay is able to detect SARS-CoV-2 Ag in
55 these specimens. For this reason we applied 150 µl of either diluted (d) or original (o)
56 specimen on the device and checked for the presence of the red control line (C) and the
57 black test line (T). This pilot approach showed that the specimens used allow a proper test

58 performance and that SARS-CoV-2 antigen can principally be detected in throat washes (I
59 and II) and BALF (III) (figure 1).


60 The analysis of the complete test cohort reveals an overall sensitivity of 29.4% and an overall
61 specificity of 86.7% (figure 2A). This means a PPV of 79.0% and a NPV of 41.9%. Next, we
62 analyzed test sensitivity and specificity in 55 samples of confirmed symptomatic (58.2%) and
63 asymptomatic (41.8%) individuals with regard to the respective PCR result, which leads to
64 sensitivity values of 22.2% (asymptomatic) and 30% (symptomatic) with specificities of
65 92.9% (asymptomatic) and 76.9% (symptomatic) (figure 2B & C). Regarding the BALF
66 specimens the test shows 54.6% sensitivity, but 100% specificity with a PPV of 100% and a
67 NPV of 28.6% (figure 2B & C). These results damp the expectation that PCR invalid samples
68 could reliably be analyzed with the rapid antigen test, although three of nine PCR invalid
69 samples are SARS-CoV-2 antigen positive, whereas 6 did not show antigen presence.

70 When checking any correlation of viral RNA load and presence of SARS-CoV-2 antigen we
71 were able to monitor two asymptomatic individuals, who were PCR positive for more than
72 five weeks before recovering in week six. Ct values ranged from 23.8 to 35.2 in patient A
73 (blue data series) and from 27.9 to 34.3 in patient B (green data series), but SARS-CoV-2
74 antigen was only detected in three samples with Ct values >30 (figure 3). The fact that
75 SARS-CoV-2 antigen is detected in samples of individuals ranging from asymptomatic +
76 PCR negative and symptomatic + PCR negative, to asymptomatic + PCR positive and
77 symptomatic + PCR positive (figure 2), suggest that this test is not suitable for routine
78 diagnostics as long as the complex relationships between viral RNA load, SARS-CoV-2
79 antigen detection, and clinical symptoms remain unsolved.

80 Regarding the correlation of PCR and the BIOCREREDIT SARS-CoV-2 antigen test, the
81 significance of the BIOCREREDIT test cannot be evaluated only based on RNA presence,
82 because both the intra-individual and the inter-individual course of viral replication kinetics
83 with prolonged viral RNA shedding and the unknown quality and quantity of accompanying
84 antigen, as also observed in the present study, make it impossible to estimate the diagnostic
85 utility of rapid antigen tests. Moreover, the limited information on host and viral factors
86 influencing shedding of SARS-CoV-2 antigens and their correlation to infectious viruses
87 impede any prognosis on infectivity. So far it also remains unclear if further common
88 phenomena such as defective interfering particles, antigen drift or antigen shift occur during
89 the current pandemic influencing the assay performance of any SARS-CoV-2 test.

90 Although it seems that exclusive antigen tests actually cannot replace PCR assays, they
91 could additionally be used to gain deeper insights into infectivity and the course of infection
92 to develop more advanced testing strategies.

93



94

95 **Figure 1: SARS-CoV-2 antigen detection.** To evaluate the suitability of specimen others
 96 than nasopharyngeal swabs 150µl of two PCR positive throat washes (I: Ct_{E-Gen}=15,6, Ct_{S-Gen}=14,8;
 97 II: Ct_{E-Gen}=14,7, Ct_{S-Gen}=14,9) and one BALF (III: Ct_{E-gen}=13,1, Ct_{S-Gen}=12,6) were
 98 used. The BIOCREREDIT Covid-19 Ag test detected SARS-CoV-2 antigen in all samples, but
 99 dilution in assay buffer (d) decreases sensitivity compared to original fluid (o). As shown by
 100 the control line the specimens allowed a proper test performance and did not contain any
 101 inhibitory substances. d=1:2 diluted, o= original

102




Figure 2: Specificity and sensitivity of SARS-CoV-2 antigen detection in PCR tested specimen. (A) Analysis of the complete test cohort (n=90), consisting of PCR positive (n=51), PCR negative (n=30) and PCR invalid samples (n=9), reveals an overall sensitivity of

29.4% and an overall specificity of 86.7%. 55 samples confirmed symptomatic or asymptomatic have been divided into (B) PCR positive (n=28) and (C) PCR negative (n=27) subgroups resulting in sensitivity values of 22.2% (asymptomatic) and 30% (symptomatic) and specificities of 92.9% (asymptomatic) and 76.9% (symptomatic). BALF= bronchoalveolar lavage fluid, TW= throat wash, BC=BIOCREDIT Covid-19 Ag test




Figure 3: Correlation of SARS-CoV-2 antigen detection with RNA load. This figure shows longitudinal SARS-CoV-2 detection by PCR in two asymptomatic individuals. In both cases SARS-CoV-2 RNA can be detected for about five weeks before recovering in week six. Antigen is only detected in one individual in three samples with Cts >30 (indicated by arrows).

- 124 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with
125 Pneumonia in China, 2019. The New England journal of medicine. 2020;382(8):727-33.
- 126 2. Fineberg HV. Ten Weeks to Crush the Curve. The New England journal of medicine.
127 2020;382(17):e37.
- 128 3. Smithgall MC, Dowlatshahi M, Spitalnik SL, Hod EA, Rai AJ. Types of Assays for SARS-CoV-2
129 Testing: A Review. Laboratory medicine. 2020;51(5):e59-e65.
- 130 4. Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M, Vijayakumar P, et al.
131 Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. The New England journal of
132 medicine. 2020.
- 133 5. Malecki M, Lusebrink J, Teves S, Wendel AF. Pharynx gargle samples are suitable for SARS-
134 CoV-2 diagnostic use and save personal protective equipment and swabs. Infection control and
135 hospital epidemiology. 2020:1-2.

136